Skip to Content

KraneShares MSCI All China Hlth Care ETF KURE

Medalist Rating as of | See Kraneshares Investment Hub

Morningstar’s Analysis KURE

Will KURE outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A lowering of Parent Pillar rating is the primary driver of KraneShares MSCI All China Hlth Care ETF's downgrade to a Morningstar Medalist Rating of Neutral from Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings KURE

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 40.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A

7.30 3.7 Mil
Healthcare

Jiangsu Hengrui Pharmaceuticals Co Ltd Class A

5.58 2.8 Mil
Healthcare

BeiGene Ltd Ordinary Shares

4.75 2.4 Mil
Healthcare

WuXi Biologics (Cayman) Inc

4.63 2.3 Mil
Healthcare

CSPC Pharmaceutical Group Ltd

3.51 1.8 Mil
Healthcare

Innovent Biologics Inc

3.38 1.7 Mil
Healthcare

Wuxi AppTec Co Ltd Class A

2.91 1.5 Mil
Healthcare

Zhangzhou Pientzehuang Pharmaceutical Co Ltd Class A

2.83 1.4 Mil
Healthcare

Aier Eye Hospital Group Co Ltd Class A

2.80 1.4 Mil
Healthcare

Chongqing Zhifei Biological Products Co Ltd Class A

2.64 1.3 Mil
Healthcare